Skip to content

Perineural Dexmedetomidine in Adductor Canal Block

Effects of Peri-neural Dexmedetomidine on the Pharmacodynamic Profile of Bupivacaine-induced Adductor Canal Block in Patients Undergoing Arthroscopic Medial Meniscectomy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03030950
Enrollment
40
Registered
2017-01-25
Start date
2018-01-25
Completion date
2018-12-05
Last updated
2019-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroscopic Medial Meniscectomy

Brief summary

This study is designed to explore the effects of peri-neural dexmedetomidine on the duration and motor sparing potentials of adductor canal block in adult patients undergoing arthroscopic medical meniscectomy in the setting of multimodal analgesia. The investigators ultimate goal is to increase the postoperative analgesic time and to preserve quadriceps muscle strength to promote safe and early ambulation.

Detailed description

Peripheral nerve blocks using long-acting local anesthetics are commonly utilized as the sole anesthetic technique or as an adjuvant to general anesthesia for post-operative pain management. However, the duration of sensory block after single dose of long acting local anesthetics is not consistently sufficient to avoid the use of postoperative opioids. Many adjuvants were added to local anesthetics to augment the potency and prolong the duration of peripheral nerve blocks. Alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of peripheral nerve block. Dexmedetomidine is a more potent and selective α-2-adrenoceptor compared to clonidine. Peri-neural dexmedetomidine was evaluated in animal studies where it prolonged the duration of sensory and motor blocks of local anesthetics without any evidence of neurotoxicity for up to 14 days after initial administration. The effectiveness of perineural dexmedetomidine in augmenting the duration of sensory block of upper limb extremity blocks is based on good quality clinical evidence. Arthroscopic knee surgery is associated with severe postoperative pain which could be adequately managed by femoral nerve block. However femoral nerve block has been associated with significant motor block and decreased quadriceps muscle strength which may delay ambulation and increase the risk of falling. More recently, adductor canal block (ACB) emerged as a selective motor sparing effective variant of femoral nerve block. Compared with baseline values, the adductor canal block reduces quadriceps muscle strength by 8%, versus 49% for the femoral nerve block. A recent dose finding MRI study reported that 20 ml of local anesthetic is the closest volume to the ED95 for adductor canal block with minimal proximal spread and an estimated success probability of 95.1% (95% credibility interval: 91-98%).

Interventions

DRUGDexmedetomidine

to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block

DRUGNormal saline

to give normal saline to the other group as a placebo

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients of aged (18-45), ASA physical status I or II undergoing arthroscopic medial meniscectomy.

Exclusion criteria

* Body mass index greater than 35 kg/m2. * Pregnancy. * Unstable coronary artery disease, congestive heart failure, or arrhythmias. * Baseline heart rate (HR) less than 60 beats/min or baseline systolic blood pressure less than 100 mmHg. * Pre-existing neurological deficits or neuropathy. * Significant psychiatric or cognitive conditions interfering with consent or assessment. * Significant renal or hepatic impairment; * Severe bronchopulmonary disease, including chronic obstructive pulmonary disease and obstructive sleep apnea. * Known contraindications to peripheral nerve block, including local skin infections, bleeding diathesis, and coagulopathy. * Allergies to local anesthetics, dexmedetomidine, or any component of multimodal analgesia.

Design outcomes

Primary

MeasureTime frameDescription
Duration of analgesia24 hoursthe time passed till the patient first analgesic request

Secondary

MeasureTime frameDescription
duration of sensory block24 hoursThe time needed to regain the patient sensation
onset of sensory blockminutesA blinded investigator will assess sensory block with pinprick test every 5 min for 30 min after injection of the study medication using a 3-point scale: 0 ═ complete loss of sensation, 1 ═ partial loss of sensation and 2 ═ normal sensation. Assessment will be done in comparison to contra-lateral area
blood pressure24 hoursmmHg
richmond agitation sedation scale24 hoursA scale to assess the patient sedation and agitation
onset of motor block (by assessment of quadriceps muscle strength)minutesThe maximum voluntary isometric contraction (MVIC) of the quadriceps femoris muscle will be measured using a handheld dynamometer
resting visual analogue score24 hoursthe grade of pain during rest as experienced by the patient, rated from 0 to 10
dynamic visual analogue score24 hoursthe grade of pain with movement as experienced by the patient, rated from 0 to 10
heart rate24 hoursbeat per minutes

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026